

## DAFTAR PUSTAKA

1. Abdul Wadood AL-Shammaree S. Semicarbazide-sensitive amine oxidase activity levels in patients with acute lymphoblastic leukemia after cytotoxic chemotherapy. *Beni-Suef Univ J Basic Appl Sci.* 2018;7(4):683–7.
2. PAPDI. Buku Ajar Ilmu Penyakit Dalam. Keenam. Setiati S, Aiwi I, Sudoyo AW, Simadibrata M, Setyohadi B, Syam AF, editors. Jakarta Pusat: Interna Publishing; 2014. 2890 p.
3. Windiastuti E, Nency YM, Mulatsih S, Sudarmanto B, Ugrasena IDG, editors. Buku Ajar Hematologi Onkologi Anak. Edisi Revi. Jakarta Pusat: Badan Penerbit Ikatan Dokter Anak Indonesia; 2018. 276–287 p.
4. American Cancer Society. Treating Acute Lymphocytic Leukemia. *Am Cancer Soc.* 2019;2019:1–29.
5. Kurniawidjaja LM, Lestari F, Tejamaya M, Ramdhan DH. Konsep Dasar Toksikologi Industri. *Fkm Ui.* 2021. 54–73 p.
6. Kalas MA, Chavez L, Leon M, Taweeseedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. *World J Hepatol.* 2021;13(11):1688–98.
7. Maharanto IY. Pengaruh Metotreksat Terhadap Kadar Serum Glutamic Pyruvic Transaminase (SGPT) dan Serum Glutamic Oxaloacetic Transaminase (SGOT) Pada Anak Leukemia Limfoblastik Akut Risiko Tinggi Fase Konsolidasi. Tesis Univ Sebel Maret. 2017;2017.
8. Malakouti M, Kataria A, Ali SK, Schenker S. Elevated liver enzymes in asymptomatic patients – what should i do? *J Clin Transl Hepatol.* 2017;5(4):394–403.
9. Vincenzi B, Russo A, Terenzio A, Galvano A, Santini D, Vorini F, et al. The use of SAME in Chemotherapy-Induced Liver Injury. *Crit Rev Oncol Hematol.* 2018;130(April):70–7.
10. American Cancer Society. About Childhood Leukemia. 2022;1–11.
11. Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, et al. Pediatric acute lymphoblastic leukemia, version 2.2020. *JNCCN J Natl Compr Cancer Netw.* 2020;18(1):81–112.
12. PDQ Pediatric Treatment Editorial Board. Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®): Health Professional Version. *PDQ Cancer Inf Summ.* 2022;1–249.
13. Perdana AB, Saputra F, Aisyi M. Update on Diagnosis of Childhood Acute Lymphoblastic Leukemia (ALL) in Indonesia. *Indones J Cancer.* 2020;14(4):115.

14. Seiter KM. Acute Lymphoblastic Leukemia (ALL). *Oncology*. 2023;
15. Parker CA, Iqbal CA, Mims MP. Acute lymphoblastic leukemia. *Tumor Board Rev Evidence-Based Case Rev Quest*. 2022;461–76.
16. Ikatan Dokter Anak Indonesia. Protokol Pengobatan Leukemia Limfoblastik Akut Anak - 2013 (Indonesian Childhood ALL - 2013 Protocol). *Ikat Dr Anak Indones*. 2013;2013:1–36.
17. Egnell C, Heyman M, Jonson OG, Raja RA, Niinimäki R, Albertsen BK, et al. Obesity as a Predictor of Treatment-Related Toxicity in Children with Acute Lymphoblastic Leukaemia. *Br J Haematol*. 2021;
18. Raetz E a. Lymphoblastic Leukemia in Children and Teens. 2022;
19. Abdulazeez W, Hematopathology O, Nashat A, Fiems M. Seasonal Variation in the Diagnosis of Acute Lymphoblastic Leukemia in Children. 2021;67(1):63–6.
20. Onciu M. Acute Lymphoblastic Leukemia. *Hematol Oncol Clin North Am*. 2009;23(4):655–74.
21. Chang JHC, Poppe MM, Hua CH, Marcus KJ, Esiashvili N. Acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2021;68(S2):1–7.
22. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. *Blood Cancer J*. 2017;7(6).
23. Greaves M. A Causal Mechanism for Childhood Acute Lymphoblastic Leukaemia. *Eur PMC Funders Gr Author Manusc*. 2020;18(8):471–84.
24. Shahriari M, Shakibazad N, Haghpanah S, Ghasemi K. Extramedullary manifestations in acute lymphoblastic leukemia in children: a systematic review and guideline-based approach of treatment. *Am J Blood Res*. 2020;10(6):360–74.
25. Maaliw RR, Alon AS, Lagman AC, Garcia MB, Susa JAB, Reyes RC, et al. A Multistage Transfer Learning Approach for Acute Lymphoblastic Leukemia Classification. 2022 IEEE 13th Annu Ubiquitous Comput Electron Mob Commun Conf UEMCON 2022. 2022;(December):488–95.
26. Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. *Haematologica*. 2020;105(11):2524–39.
27. UKK Hematologi Onkologi IDAI. Buku Panduan Protokol Leukemia Limfoblastik Akut 2018. 2018;18–9.
28. Trefts E, Gannon M, Wasserman DH. The liver. 2018;27(21).
29. Paris J, Henderson NC. Liver zonation, revisited. *Hepatology*. 2022;76(4):1219–30.
30. Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the

Liver. Clin Liver Dis. 2017;21(1):1–20.

31. Lala V, M Z, Minter D. Liver Function Tests. In: StatPearls [Internet]. Treasure Island (FL). 2023.
32. Martin P, Friedman LS. Assessment of liver function and diagnostic studies. Fourth Edi. Handbook of Liver Disease. Elsevier Inc.; 2018. 1–17 p.
33. Vagvala SH, O'Connor SD. Imaging of abnormal liver function tests. Clin Liver Dis. 2018;11(5):128–34.
34. Dasgupta A, Wahed A. Liver diseases and liver function tests. Clin Chem Immunol Lab Qual Control. 2021;207–27.
35. Fernández Ventureira V, Ros Arnal I, Rodríguez Martínez G, García Rodríguez B, García Romero R, Ubalde Sainz E. Evaluation of liver function tests in the paediatric patient. An Pediatr. 2021;94(6):359–65.
36. Islam T, Rahman AKMS, Hasan MK, Jahan F, Mondal MC, Ferdoushi S, et al. Liver Function Tests in Patients of Acute Leukemia before and after Induction Chemotherapy. J Biosci Med. 2020;08(02):110–21.
37. Komalasari K., Ariawati K, Niruri R. Evaluasi Peningkatan Kadar Bilirubin Akibat Kemoterapi Metotreksat Dosis Tinggi dan 6-Merkaptopurin Pada Anak dengan Leukemia Limfoblastik Akut di Rumah Sakit Umum Pusat Sanglah. Sari Pediatr. 2014;2014.
38. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE).v.5.0. Cancer Ther Eval Progr. 2017;155.
39. Ramadori G, Cameron S. Effects of systemic chemotherapy on the liver. Ann Hepatol. 2010;9(2):133–43.
40. Calistri L, Rastrelli V, Nardi C, Maraghelli D, Vidali S, Pietragalla M, et al. Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis. World J Gastroenterol. 2021;27(46):7866–93.
41. Sajith M, Pawar A, Bafna V, Bartakke S. High-dose methotrexate-induced fulminant hepatic failure and pancytopenia in an acute lymphoblastic leukaemia paediatric patient. Eur J Hosp Pharm. 2020;27(3):178–80.
42. Zeien J, Qiu W, Triay M, Dhaibar HA, Cruz-Topete D, Cornett EM, et al. Clinical implications of chemotherapeutic agent organ toxicity on perioperative care. Biomed Pharmacother. 2022;146(December 2021):112503.
43. Katzung BG. Basic & Clinical Pharmacology. Vol. 14, McGraw-Hill Education. 2018. 293–300 p.
44. Tripodi SI, Bergami E, Panigari A, Caissutti V, Brovia C, De Cicco M, et al. The role of nutrition in children with cancer. Tumori. 2023;109(1):19–27.

45. Menteri Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 2 Tahun 2020 Tentang Standar Antropometri Anak. 2020;21(1):1–9.
46. Jannat M, Morshed AA, Anwer S, Islam S. Effect of Chemotherapy on Liver Function During Induction of Remission in Children with Acute Lymphoblastic Leukemia Receiving Standard Protocol. *J Dhaka Med Coll.* 2021;29(1):33–7.
47. (MD) B. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Natl Inst Diabetes Dig Kidney Dis. 2012;(Md).
48. Conway R, Carey JJ. Risk of liver disease in methotrexate. *World J Hepatol*. 2017;9(26):1081–114.
49. Kumar GVN, Hoshitsuki K, Rathod S, Ramsey MJ, Kokai L, Kershaw EE, et al. Mechanistic studies of PEG-asparaginase-induced liver injury and hepatic steatosis in mice. *Acta Pharm Sin B.* 2021;11(12):3779–90.
50. Diseases K. Asparaginase. 2018;(Md):1–11.
51. Kamal N, Koh C, Samala N, Fontana RJ, Stolz A, Durazo F, et al. Asparaginase-induced Hepatotoxicity: Rapid Development of Cholestasis and Hepatic Steatosis. *HHS Public Access.* 2020;176(5).
52. Benyamin T, Lubis B. Comparison of serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase levels between induction and consolidation phase chemotherapy in children with standard risk of acute lymphoblastic leukemia. 2022;62(08):3899–910.
53. Kamilah S, Mayetti M, Deswita D. Karakteristik Anak Leukemia Limfoblastik Akut yang Menjalani Kemoterapi. *J Keperawatan Silampari.* 2023;6(2):1040–5.
54. Hoover K, Higginbotham K. Epstein-Barr Virus Treatment / Management. 2023;
55. Alfi Karniawaty, Putri M, Marlia Kurniawati L. Perubahan Status Gizi pada Anak Leukemia Limfoblastik Akut Selama Fase Kemoterapi. *Bandung Conf Ser Med Sci.* 2023;3(1):3–6.
56. Rompies R, Amelia SP, Gunawan S. Perubahan Status Gizi pada Anak dengan Leukemia Limfoblastik Akut Selama Terapi. *e-CliniC.* 2019;8(1):152–7.
57. Larasati M. Perbandingan stratifikasi risiko leukemia limfoblastik akut dengan penambahan pemeriksaan imunofenotiping pada luaran kemoterapi Indonesian Protocol Acute Lymphoblastic Leukemia (ALL) 2013 Fase Induksi di RSUD Dr. Soetomo Surabaya (Comparison the risk str. 2016;p22-46.
58. Ali A, El-Hefedy A, Sayed D, Osman A. Clinicolaboratory Characteristics



and Outcome of Pediatric Acute Lymphoblastic Leukemia in a Resource-Limited Setting: A Study from South Egypt. *Res Oncol*. 2022;0(0):1–8.

59. Kamima K, Gatot D, Hadinegoro SRS. Profil Antioksidan dan Oksidan Pasien Anak dengan Leukemia Limfoblastik Akut pada Kemoterapi Fase Induksi ( Studi Pendahuluan). *Sari Pediatr*. 2017;11(4):282.
60. Ariawati, K ; Windiastuti, E ; Gatot D. Toksisitas Kemoterapi Leukemia Limfoblastik Akut pada Fase Induksi dan Profilaksis Susunan Saraf Pusat dengan Metotreksat 1 gram. 2007;9.
61. Hikmat AAF, Andarsini MR, Setyoboedi B, Larasati MCS, Cahyadi A, Ugrasena IDG. Risk Factors for Hepatotoxicity From L-Asparaginase Chemotherapy In Children With Acute Lymphoblastic Leukemia. *Pharmacogn J*. 2022;14(6):921–7.
62. Skrypnyk IM, Maslova GS. Overweight and Obesity as Risk Factors for Chemotherapy-Induced Hepatotoxicity in Patients with Acute Lymphoblastic Leukemia. *NCRM Work Pap*. 2022;2(4):1–10.
63. Gómez-Hernández A, Beneit N, Díaz-Castroverde S, Escribano Ó. Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications. *Int J Endocrinol*. 2016;2016.
64. Mulyono HA, Martin A, Johan J, Hadisono H. Perbedaan Rerata Kadar Serum Glutamic Pyruvate Transaminase Pada Pria Dan Wanita Penderita Non-Alcoholic Fatty Liver. *Sebatik*. 2023;27(1):355–62.
65. Manna P, Jain SK. Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies. *Metab Syndr Relat Disord*. 2015;13(10):423–44.
66. Schmidt S, Messner CJ, Gaiser C, Hämmerli C, Suter-Dick L. Methotrexate-Induced Liver Injury Is Associated with Oxidative Stress, Impaired Mitochondrial Respiration, and Endoplasmic Reticulum Stress In Vitro. *Int J Mol Sci*. 2022;23(23).
67. Seo YJ, Shim YS, Lee HS, Hwang JS. Updated reference ranges for aminotransferase levels of Korean children and young adolescents based on the risk factors for metabolic syndrome. *Sci Rep*. 2022;12(1):1–16.
68. Suchy FJ. Functional development of the liver. *Liver Dis Child* Fourth Ed. 2011;(May):10–23.